🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals

← All drug comparisons

Lopressor vs Bystolic

Metoprolol  ·  Nebivolol

Both are beta blockers. Here is how Lopressor and Bystolic compare on class, mechanism, dosing, approval and supply.

At a glance

LopressorMetoprolol
BystolicNebivolol
Brand names
Lopressor / Toprol-XL
Bystolic
Drug class
Beta blocker
Beta blocker
Route
Oral
Oral
Marketed by
Validus Pharmaceuticals
Allergan
First FDA approval
7 Aug 1978
17 Dec 2007
US shortage
Not listed
Not listed

Key differences

What each one treats

LopressorMetoprolol

1 IND ICATIONS AND USAGE LOPRESSOR is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3 ) 1.1 Hypertension LOPRESSOR is indicated for the treatment of hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharma…

BystolicNebivolol

1. INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. BYSTOLIC may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction wi…

How each one works

LopressorBeta blocker

12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1 -selectivity of metoprolol has been confirmed by the following: (1) In normal sub…

BystolicBeta blocker

12.1 Mechanism of Action The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.

Related comparisons

Zebeta VS Lopressor Zebeta VS Bystolic Lopressor VS Coreg Coreg VS Bystolic

Read more

Lopressor profile Bystolic profile Beta Blockers All comparisons
This is not medical advice, and not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

Class and summary text is written by the Priya Life Science editorial team. Label, mechanism, route, manufacturer and approval data come from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. Approvals, indications and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions — a drug approved in one may not be approved, or may carry a different name, in another.